Navigation Links
WHO Introduces the Helminth Drug Initiative With Special Supplement in the Expert Opinion on Drug Discovery
Date:10/18/2007

LONDON, October 18 /PRNewswire/ -- Helminth infections are responsible for a huge health burden on developing country populations, and the number of drugs available to treat them is incredibly limited.

The paucity of products in development for helminth diseases has necessitated a focused initiative to boost the R&D pipeline for these diseases. Consultation meetings organised by the WHO Research and Training in Tropical Diseases (TDR) Programme in collaboration with the Japanese Society of Parasitology led to the establishment of the Helminth Drug Initiative (HDI), which aims to facilitate R&D against human parasitic worm infections.

In a freely available 103-page peer-reviewed special issue of Expert Opinion on Drug Discovery, the rationale behind the HDI is documented, as well as reports of technical consultations and recommendations that led to the initial establishment of the Initiative within TDR.

"The Helminth Drug Initiative is an integral part of an innovative drug discovery platform established by TDR based on a coordinated network of partners from industry and academia from the developed and developing countries ", commented Dr Solomon Nwaka, who leads drug discovery efforts and the HDI.

The special issue focusing on the Helminth Drug Initiative of the Expert Opinion on Drug Discovery is available for free download at: http://www.pjbpubs.com/uploads/content/expertopin/eodc_freedownload.htm.

About Expert Opinion

The Expert Opinion series provides systematic and authoritative reviews to support every stage of the drug discovery and R&D pipeline from target to market. Each of the eleven journals in the series covers a specific aspect of the pharmaceutical pipeline.

The series contains the following journals: Expert Opinion on Biological Therapy, Expert Opinion on Drug Delivery, Expert Opinion on Drug Discovery, Expert Opinion on Drug Metabolism & Toxicology, Expert Opinion on Drug Safety, Expert Opinion on Emerging Drugs, Expert Opinion on Investigational Drugs, Expert Opinion on Medical Diagnostics, Expert Opinion on Pharmacotherapy, Expert Opinion on Therapeutic Patents, and Expert Opinion on Therapeutic Targets.

For further information:

Phil Garner, Publisher

Telephone: +44-(0)20-7017-6775

Email: phil.garner@informa.com

Website: http://www.expertopin.com


'/>"/>
SOURCE Expert Opinion
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GE Healthcare introduces MR imaging product
2. Online fishing site introduces interactive maps
3. GE introduces remotely hosted health services
4. Norlight introduces new e-mail security service
5. Angel network introduces ePlan
6. RedPrairie Corp. introduces new supply chain software
7. GE introduces compact ultrasound system for women
8. MailFoundry introduces new e-mail archive product
9. Madison biotech introduces drug discovery advance
10. Alfalight introduces new 25-watt pump module
11. Wisconsin introduces new state IT plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):